<div class="container-fluid background_merckDetail">

    <div class="row justify-content-between p-5 ml-1">
        <div>
            <h1 class="merckFont colouroncology">Merck</h1>
        </div>
        <div class="d-flex">
            <div class="positionhead pt-2 pr-4 border_home">
                <h2 class="merckFont coloronco">ONCOGENIC PATHWAYS</h2>
            </div>
            <div class="positionhome pl-4">
                <a [routerLink]="'/'"> <img src="assets/buttons/home-btn.png"
                        alt="Home"
                        height="50"
                        width="50"></a>
            </div>
        </div>
    </div>
    <ng-container [ngSwitch]="navigationHolder.currentSection">
        <ng-container *ngSwitchCase="0">
            <div class="main-content">
                <div class="row">
                    <div class="col-12">
                        <h2 class="coloronco mb-5"><b>M7583*</b>
                            <br> (BTK inhibitor)</h2>
                    </div>
                    <div class="col-lg-6 col-md-12 col-sm-12">
                        <p class="font-weight-bold f-16 pl-4">Proposed profile</p>
                        <ul class="small-li">
                            <li>M7583* is an investigational, ATP-competitive, irreversible BTK inhibitor.<sup>1</sup>
                                This molecule is currently under clinical investigation and has not been proven to
                                be safe and effective</li>
                            <li>BTK is a key component of BCR signaling that regulates B-cell proliferation and
                               survival<sup>2,3</sup>
                            </li>
                            <li>The BCR pathway is implicated in the pathogenesis of B-cell malignancies such as 
                                diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), B- cell chronic
                                lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM),
                                and multiple myeloma (MM)<sup>3,4</sup></li>
                            <li>M7583 is currently being investigated as potential therapy for various B-cell
                                malignancies<sup>3</sup>
                            </li>
                            <li>Development of and clinical/preclinical investigation of BTK inhibitors may provide
                                 additional insight into treatment of patient groups who have not shown significant
                                 response to other therapies<sup>3</sup></li>
                        </ul>
                    </div>
                    <div class="col-lg-6 col-md-12 col-sm-12 text-center">
                        <img src="assets/content/ONCO-PATHWAY/m7583-moa.png"
                            width="500px">
                    </div>


                </div>
            </div>
            <nav>
                <div class="col-12">
                    <div class="d-flex justify-content-center mt-4">

                        <navigation-footer [navigationPanes]="navigationHolder"></navigation-footer>
                    </div>
                </div>
            </nav>



            <div class="row pt-5 pl-4">
                <div class="col-12 needs-row-parent-pt-5-pl-4">

                    <div class="d-flex justify-content-between footer-disclaimers">
                        <div class="p-2 f-10 text-dark">
                            <app-pipeline-compounds></app-pipeline-compounds>
                            <!--
                        GLOBAL: Adjust order /formatting (not bolded)
                        spacing of footer should go:
                        Pipeline disclaimer (line break)
                        Abbreviations (line break)
                        Asset disclaimer (line break)
                        Refs (line break) -->

                            BCR, B-cell antigen receptor; BTK, Bruton tyrosine kinase;
                            elf4E, Eukaryotic translation initiation factor 4E; GSK-3,
                            glycogen synthase kinase 3; LYN, tyrosine-protein kinase Lyn;
                            mTOR, mammalian target of rapamycin; <br />
                            NF-kβ, nuclear factor kappa-light-chain-enhancer
                            of activated B cells; p70S6K, ribosomal protein S6 kinase beta-1; PI3K,
                            phosphatidylinositide 3-kinase; PKC, protein kinase C; PLCγ2,
                            phospholipase Cγ2; SYK, spleen tyrosine kinase.<br><br>
                            *M7583 is under clinical investigation and has
                            not been proven to be safe and effective.
                            There is no guarantee M7583 will be approved in the sought-after indications.
                            The relevance of these preclinical findings on the efficacy and safety in the<br>
                            clinical setting has not been
                            established.
                            <br><br>1. Herman SEM, et al. Blood 2011;117:6287-96. 2.
                            Gaudio E, et al. Cancer Res 2017;77(13 Suppl):Abstract 4182 and poster (AACR 2017).
                            3. Hendricks RW, et al. Nat Cancer Rev 2014;14:219-32.
                            4. Woyach JA, et al.
                            Blood 2012;120:1175-84.
                        </div>
                        <div class="p-2 f-10 text-dark d-flex align-items-end zinc-code">GBPMLR/MULOP/0819/0016
                            September 2019</div>
                    </div>



                </div>
            </div>
        </ng-container>
        <ng-container *ngSwitchCase="1">
            <!-- Section 2 -->
            <div class="main-content">
                <div class="row">
                    <div class="col-12">
                        <h2 class="coloronco mb-5"><b>M7583*</b>
                            <br> (BTK inhibitor)</h2>
                    </div>
                    <div class="col-12">
                        <p class="font-weight-bold f-16"> Clinical trial program overview</p>
                        <ul>
                            <li>M7583 is currently being evaluated in 1 first-in-human phase I study</li>
                        </ul>
                        <div class="table-responsive">
                            <table class="table table-striped">
                                <thead class="btn-oncology text-white">
                                    <tr>
                                        <th class="ImageColumn">Enrolling</th>
                                        <th>Clinical Trial</th>
                                        <th>Line </th>
                                        <th>Phase</th>
                                        <th>M7583 Treatment</th>
                                        <th>ClinicalTrials.gov Identifier</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr class="bg-white">
                                        <td></td>
                                        <td colspan="5"
                                            class="font-weight-bold text-black">Hematologic malignancies</td>
                                    </tr>
                                    <tr class="bg-light">
                                        <td class="ImageColumn"><img src="assets/indicators/study-closed.png"
                                                width="25"
                                                height="25"></td>
                                        <td>B-cell malignancies</td>
                                        <td>2L+*</td>
                                        <td>Phase I/II</td>
                                        <td>Monotherapy</td>
                                        <td>NCT02825836</td>
                                    </tr>
                                    <tr class="bg-white">
                                        <td></td>
                                        <td colspan="5"
                                            class="font-weight-bold text-black">Healthy volunteers</td>
                                    </tr>
                                    <tr class="bg-light">
                                        <td class="ImageColumn"><img src="assets/indicators/study-closed.png"
                                                width="25"
                                                height="25"></td>
                                        <td>Bioavailability</td>
                                        <td>–</td>
                                        <td>Phase I</td>
                                        <td>Monotherapy</td>
                                        <td>NCT03297983</td>
                                    </tr>
                                </tbody>
                            </table>
                            <div class="d-flex justify-content-end">
                                <img src="assets/indicators/study-recruiting.png"
                                    width="25"
                                    height="25"
                                    title="Study currently recruiting"> <span class="f-14"> &nbsp;&nbsp; Study currently
                                    recruiting &nbsp;&nbsp; </span><img src="assets/indicators/study-closed.png"
                                    width="25"
                                    height="25"
                                    title="Study closed for enrollment"> <span class="f-14"> &nbsp;&nbsp; Study closed
                                    for enrollment&nbsp;&nbsp;</span>
                            </div>
                        </div>
                    </div>

                </div>
            </div>

            <nav>
                <div class="col-12">
                    <div class="d-flex justify-content-center mt-4">

                        <navigation-footer [navigationPanes]="navigationHolder"></navigation-footer>
                    </div>
                </div>
            </nav>



            <!-- Footer -->
            <div class="row pt-5 pl-4">
                <div class="col-12 needs-row-parent-pt-5-pl-4">
                    <div class="d-flex justify-content-between footer-disclaimers">
                        <div class="p-2 f-10 text-dark">
                            <app-pipeline-compounds></app-pipeline-compounds>
                            *This study is ongoing, but not recruiting participants.
                        </div>
                        <div class="p-2 f-10 text-dark d-flex align-items-end zinc-code">GBPMLR/MULOP/0819/0016
                            September 2019</div>
                    </div>
                </div>
            </div>
        </ng-container>
    </ng-container>
</div>